Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipranavir/Ritonavir and Tenofovir PK Interaction Study
NCT02251145Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2002
- Primary completion
- Jun 2002
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of tipranavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under plasma concentration time curve from 0-24 hours for tenofovir, Area under plasma concentration time curve from 0-12 hours for tipranavir/ritonavir and 2 more. Started May 2002; status: completed.
02
Drugs
tipranavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02251145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02251145.